1-10 of 10
Guy Pratt, MD FRCP FRCPath
Close
Sort by
Journal Articles

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

Mark T Drayson, MD PhD, Stella Bowcock, MDMA, Tim Planche, MDPhD, Gulnaz Iqbal, PhD, Jill Wood, MPH, Kerry Raynes, MSc, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Peter Hawkey, FRCPath, Helen Higgins, MSc, Janet Dunn, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 903.
https://doi.org/10.1182/blood.V130.Suppl_1.903.903
Published: 2017
Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Michael Chapman, PhD MRCP, FRCPath, Jonathan Sive, John Ambrose, Claire Roddie, PhD MD, Nicholas Counsell, Paul Smith, Nivette Braganza, Toyin Adedayo, Rakesh Popat, MD PhD, James D Cavenagh, Matthew J. Streetly, BMBS, PhD MRCP, FRCPath, Roger G. Owen, MD, Stephen Schey, MBBS, Mickey Koh, MD PhD, Josephine Crowe, Michael F. Quinn, FRCPath, MB, MD MRCP, Shirley D'Sa, MD FRCP, FRCPath, Andres E. Virchis, FRCP, FRCPath, Gordon Cook, PhD, Charles R Crawley, Guy Pratt, MD FRCP, FRCPath, Mark Cook, MBChB,PhD, Laura Clifton-Hadley, PhDBSc, Javier Herrero, PhD, Kwee Yong, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 267.
https://doi.org/10.1182/blood.V130.Suppl_1.267.267
Published: 2017
Journal Articles

Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy: Implication for Patient Management

Ilaria Chicca, PhD, Jennifer LJ Heaney, PhD, Gulnaz Iqbal, PhD, Stella Bowcock, MDMA, Tim Planche, MDPhD, Jill Wood, MPH, Kerry Raynes, MSc, Peter Hawkey, FRCPath, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Helen Higgins, MSc, Janet Dunn, PhD, Mark T Drayson, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3036.
https://doi.org/10.1182/blood.V130.Suppl_1.3036.3036
Published: 2017
Journal Articles

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Marwan Kwok, MBBS,MRCP, Andy Rawstron, PhD, Angelo Agathanggelou, PhD, Anshita Goel, PhD, Ceri Oldreive, PhD, Rhiannon E Jones, PhD, Samantha Drennan, PhD, Archana Sharma-Oates, PhD, Paul Evans, PhD, Edward Smith, MSc, Jingwen Mao, Jamie Beaumont, Jusveen Rai, Mayumi Hamada, MB ChB, Surita Dalal, PhD, Naheema Gordon, MSc, Nicholas Davies, PhD, Helen Parry, MB ChB, MRCP, PhD, Andrew Beggs, MBBS, PhD FRCS, Talha Munir, Paul Moreton, MD MRCP, FRCPath, Shankara Paneesha, MD MRCP, FRCPath, Guy Pratt, MD FRCP, FRCPath, Malcolm Taylor, PhD, Francesco Forconi, MD DM, PhD FRCPath, Duncan M Baird, PhD, Jean-Baptiste Cazier, PhD, Paul Moss, MBBS, PhD FRCP, Peter Hillmen, MBChB, PhD, Tatjana Stankovic, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3004.
https://doi.org/10.1182/blood.V130.Suppl_1.3004.3004
Published: 2017
Journal Articles

Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients

Stella Bowcock, MDMA, Catherine Atkin, MD, Gulnaz Iqbal, PhD, Tim Planche, MDPhD, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Jill Wood, MPH, Kerry Raynes, MSc, Eric Low, BSc, Helen Higgins, MSc, Janet Dunn, PhD, Mark T Drayson, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2132.
https://doi.org/10.1182/blood.V130.Suppl_1.2132.2132
Published: 2017
Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Rakesh Popat, MD PhD, Ruth Mary De Tute, BSc,MSc, Nicholas Counsell, Dunnya De-Silva, Beth Phillips, MBBS, FRCPath, BSc, James D Cavenagh, Toyin Adedayo, Nivette Braganza, Claire Roddie, PhD MD, Mathew Streetly, Stephen Schey, MBBS, Mickey Koh, MD PhD, Josephine Crowe, Michael F. Quinn, FRCPath, MB, MD MRCP, Shirley D'Sa, MD FRCP, FRCPath, Andres E. Virchis, FRCP, FRCPath, Gordon Cook, PhD, Charles R Crawley, Guy Pratt, MD FRCP, FRCPath, Mark Cook, MBChB,PhD, Paul Smith, Laura Clifton-Hadley, PhDBSc, Neil Rabin, Roger G Owen, MD, Kwee Yong, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1864.
https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864
Published: 2017
Journal Articles

Inhibition of Btk Does Not Block Platelet Activation By GPVI: Studies with Ibrunitib, Acalabrutinib and Patients with X-Linked Agammaglobulinaemia

Phillip LR Nicolson, MA, MBBChir, MRCP, Stephanie Watson, BSc, Craig E Hughes, BSc, PhD, Alexander T Hardy, BSc, Callum N Watson, BSc, Samantha J Montague, BSc, PhD, Michael G Tomlinson, BSc, PhD, Guy Pratt, MD FRCP, FRCPath, Steve P Watson, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1030.
https://doi.org/10.1182/blood.V130.Suppl_1.1030.1030
Published: 2017
Journal Articles

An ABVD-Based Approach Confers Superior Outcomes for Adolescent and Young Adult Patients Compared to Other Adults with Advanced Classical Hodgkin Lymphoma

David M Burns, BSc,MBBS,MRCP, Andrew Bacon, BSc, MSc, Timothy HT Wong, MBBChir, Guy Pratt, MD FRCP, FRCPath, Fiona J Clark, MBBChir, FRCP, FRCPath, Premini Mahendra, MD FRCP, FRCPath, Sridhar Chaganti, MDPhDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4083.
https://doi.org/10.1182/blood.V130.Suppl_1.4083.4083
Published: 2017
Journal Articles

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Sidra Ellis, Farzana Begum, Jack Kendall, David C Johnson, Roger G Owen, MD, Mark T Drayson, MD PhD, Louise Flanagan, Debbie Sherratt, Walter M Gregory, PhD, Graham Jackson, MDPhD, Guy Pratt, MD FRCP, FRCPath, Gordon Cook, MD PhD, Samantha Hinsley, Sarah Brown, Matthew W Jenner, Martin F Kaiser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1767.
https://doi.org/10.1182/blood.V130.Suppl_1.1767.1767
Published: 2017
Journal Articles

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstrőM's Macroglobulinemia: A Randomised Phase II Study

Rebecca L Auer, MD PhD, Roger G Owen, Shirley D'Sa, Guy Pratt, MD FRCP FRCPath, Bilyana Popova, Laura Clifton Hadley, Oliver Schofield, Nicholas Counsell, Paul Smith
Journal: Blood
Blood (2016) 128 (22): 618.
https://doi.org/10.1182/blood.V128.22.618.618
Published: 2016